Related Experiment Video

Updated: Jan 5, 2026

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
12:22

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

34.1K

Drug resistance in papillary RCC: from putative mechanisms to clinical practicalities

Anna Brodziak1,2,3, Paweł Sobczuk1,2,3, Ewa Bartnik4,5

  • 1Department of Oncology, Military Institute of Medicine, Warsaw, Poland.

Nature Reviews. Urology
|October 12, 2019
PubMed

Insights

Papillary renal cell carcinoma (pRCC) drug resistance involves complex genetic and signaling pathway alterations. Understanding these mechanisms is crucial for developing targeted therapies and improving patient outcomes in this RCC subtype.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacogenomics

Background:

  • Papillary renal cell carcinoma (pRCC) is the second most common kidney cancer subtype.
  • Limited pharmacogenomics research and laboratory models exist for pRCC.
  • pRCC exhibits diverse molecular mechanisms for drug resistance compared to clear-cell RCC.

Purpose of the Study:

  • To highlight the need for more pharmacogenomics studies in pRCC.
  • To emphasize the importance of utilizing pRCC laboratory models.
  • To detail the molecular mechanisms underlying pRCC development and drug resistance.

Main Methods:

  • Review of existing literature on pRCC molecular mechanisms.
  • Analysis of genetic alterations, signaling pathway dysregulation, and cellular processes involved in pRCC drug resistance.
  • Identification of key pathways and interactions contributing to resistance.

Main Results:

  • pRCC drug resistance is driven by genetic alterations (e.g., RTK activation, RALBP1 inhibition).
  • Dysregulated signaling pathways (e.g., PI3K-AKT, MAPK) and cellular processes (e.g., apoptosis, EMT) contribute to resistance.
  • Interactions between cancer cells and their environment, including MMP activation, play a role.

Conclusions:

  • Understanding pRCC resistance mechanisms is vital for advancing drug discovery.
  • Novel resistance biomarkers are needed for improved patient prognosis, stratification, and therapeutic development.
  • Further research using pRCC models is essential to develop effective treatments.

More Related Videos

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

11.1K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.5K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Factors Affecting Renal Clearance: Renal Impairment01:17

Factors Affecting Renal Clearance: Renal Impairment

Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
389